Clinical Trials Logo

Pulmonary Tuberculosis clinical trials

View clinical trials related to Pulmonary Tuberculosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04260477 Active, not recruiting - Tuberculosis Clinical Trials

Novel Triple-dose Tuberculosis Retreatment Regimen

Tri-Do-Re
Start date: March 1, 2021
Phase: Phase 3
Study type: Interventional

To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent Tuberculosis (TB).

NCT ID: NCT04081077 Active, not recruiting - Clinical trials for Pulmonary Tuberculosis

PRACTECAL-PKPD Sub Study

PRACTECAL-PKPD
Start date: August 6, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

PRACTECAL-PKPD is an exploratory pharmacokinetic and pharmacodynamic sub-study investigating the relationship between the patients' exposure to anti- tuberculosis (TB) drugs in the TB-PRACTECAL trial investigational regimens and their respective treatment outcomes.

NCT ID: NCT01691534 Active, not recruiting - Clinical trials for Pulmonary Tuberculosis

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)

NC-003
Start date: September 2012
Phase: Phase 2
Study type: Interventional

The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of TMC207 plus PA-824 plus Pyrazinamide plus Clofazimine, TMC207 plus PA-824 plus Pyrazinamide, TMC207 plus PA-824 plus Clofazimine alone, TMC207 plus Pyrazinamide plus Clofazimine, Pyrazinamide alone, Clofazimine alone, and standard first line TB treatment as per South African TB Guidelines (Rifafour e-275) as determined by the rate of change of log CFU per ml sputum over the time period Day 0-14 in participants with smear positive pulmonary tuberculosis (TB). A control group will receive standard treatment.